D
uring the past three decades, the use of fertility treatment has increased. 1 As the field strives for continuous improvement of the treatments, new technologies, medications, and procedures have been introduced. Reports from 2014 estimated that worldwide 350,000 children have been born as a result of in vitro fertilization (IVF) or intracytoplasmic sperm injection each year. 2 In addition, a large number of children were conceived by less invasive procedures, such as ovulation induction or intrauterine insemination. 3 Fertility treatment bypasses natural conception by means of hormonal stimulation of the woman and mechanical and chemical manipulation of the gametes and the early embryo. 4 Hence, concerns have been raised about potentially negative consequences for the developing child. Although previous research has reported adverse pregnancy outcomes, even in singleton births, 5 studies investigating potential longterm health effects are sparse. 6 Prenatal brain development is a highly complex process that may easily be disturbed, and exposures during crucial stages of development may result in disease or dysfunction later in life. 7 A few studies have suggested that fertility treatment may be associated with an increased risk of childhood epilepsy. 8, 9 However, it remains unknown whether this risk is related to the hormonal stimulation, the in vitro manipulation of gametes and embryos, or perhaps due to confounding by indication, that is, factors contributing both to the underlying parental infertility 10 and the development of childhood epilepsy. In addition, it has not been studied whether fertility treatment is associated with an increased risk of specific types of epilepsy.
The aim of the present study was to investigate the association between fertility treatment and the development of childhood epilepsy within a large nationwide birth cohort using information from high-quality health registers. In addition, we aimed to address the possible effects of specific treatments and indications, as well as the risk of the development of specific types of childhood epilepsy.
METHODS

Design and Population
In this nationwide birth cohort study, we included all pregnancies in Denmark resulting in a live-born singleton child from 1 January 1995 to 31 December 2003. The study population was identified from the Danish Medical Birth Registry in which all children born in Denmark have been registered since 1973. 11 Using the unique personal identification number assigned to all legal Danish residents, we linked individual-level information from the Danish Medical Birth Registry to information from the Danish IVF register, 12 the Danish National Prescription Registry, 13 and the Danish National Patient Register.
14 In addition, we obtained information on maternal education as well as emigration and vital status of the children from Statistics Denmark.
15
As the minimum age of mothers in the cohort who had received fertility treatment was 20 years, we excluded spontaneously conceived children born to mothers younger than 20 years.
Fertility Treatment
IVF and intracytoplasmic sperm injection constitute the most invasive types of fertility treatment. Follicle-stimulating hormone and human chorionic gonadotropin are used to induce ovulation, 16, 17 after which oocytes are retrieved by transvaginal aspiration and fertilized in vitro. In the case of intracytoplasmic sperm injection, a single spermatozoon is injected into the oocyte. 4 Children conceived by IVF and intracytoplasmic sperm injection were identified from the Danish IVF register along with information about the treatment and the treatment indications. Since 1994, it has been mandatory for all public and private fertility clinics in Denmark to report each initiated IVF cycle to the Danish IVF register. 12 Less invasive types of fertility treatment comprise ovulation induction with or without intrauterine insemination. One of the most frequently used hormones for ovulation induction is clomiphene citrate administrated on days 3 to 7 of the menstrual cycle. Additional hormone supplementation may also be required. If intrauterine insemination is performed, a concentrated sperm sample is introduced into the woman's uterine cavity at the time of ovulation. 4 Children conceived by ovulation induction or intrauterine insemination are not included in the Danish IVF register and were identified from the Danish National Prescription Registry from records of maternal hormonal treatment. Since 1995, all redeemed prescriptions in Denmark have been reported to the register according to the Anatomical Therapeutic Codes (ATC) for drugs along with the dispensing date. 13 The hormone prescriptions consistent with ovulation induction or intrauterine insemination treatment had to be redeemed within 12 weeks before to four weeks after the last menstrual period recorded in the Danish Medical Birth Registry. This time span was chosen because hormonal treatment may be prescribed for up to 12 weeks at a time. Pregnancies recorded in the Danish IVF register were not included in the ovulation induction or intrauterine insemination group. From the Danish national health registers, it is impossible to distinguish ovulation induction from intrauterine insemination and whether the infertility was due to maternal or paternal factors.
Epilepsy
Children developing epilepsy were identified from the Danish National Patient Register and from redeemed prescriptions in the Danish National Prescription Registry. The Danish National Patient Register holds information on all hospital contacts (in-and outpatient visits) in Denmark since 1995, including the date of the contact, as well as physicianassigned diagnoses. The diagnoses are classified according to the International Classification of Diseases (ICD). 14 We defined epilepsy as either a primary diagnosis of epilepsy or status epilepticus (ICD, 10th edition [ICD-10]: G40 or G41), or the redemption of at least two separate prescriptions for any antiepileptic drug (ATC: N03A or N05BA09 18 ). Using both data sources ensured identification of children diagnosed with epilepsy at both private clinics and hospitals.
Statistical Analyses
The analyses were performed in Stata 14 (StataCorp, TX). All children were followed from the date of birth to the date of the first diagnosis of epilepsy or the first prescription for any antiepileptic drug, the date of emigration or death, or until the end of follow-up (31 December 2013), whichever occurred first. Cox proportional hazards regression was used to estimate hazard rate ratios (HRs) and 95% confidence intervals (CIs). The proportional hazards assumption was checked graphically using log-log plots and predicted survival plots. Robust standard errors were used to account for correlations between siblings in the cohort.
The following potential confounders, selected a priori on the basis of directed acyclic graphs, 19 were included in the analyses: maternal age at birth (continuous using fractional polynomials), maternal smoking during pregnancy (yes or no), maternal ethnicity (Western or non-Western) 20 ascertained from the Danish Medical Birth Registry, maternal education (five groups), maternal diagnosis of epilepsy in the Danish National Patient Register before birth (yes or no), and child's year of birth (1995-1997, 1998-2000, 2001-2003) .
Missing data were imputed using multiple imputation under the assumption of data being missing at random. 21 The covariate containing the largest proportion of missing observations was maternal ethnicity (23%). Complete exposure and outcome information was available for all participants in the primary analyses (see eAppendix 1; http://links.lww. com/EDE/B155 for details regarding the multiple imputation).
We performed a number of subgroup analyses estimating (1) the risk of specific types of childhood epilepsy believed to be of genetic (idiopathic generalized epilepsy, ICD-10: G403) and structural origin (focal epilepsy, ICD-10: G401, G402) [22] [23] [24] and (2) the risk associated with specific types of hormones used as monotherapy for ovulation induction or intrauterine insemination (clomiphene citrate, follicle-stimulating hormone, human chorionic gonadotropin). For IVF or intracytoplasmic sperm injection, we assessed the risk associated with (3) the specific procedure (IVF or intracytoplasmic sperm injection), (4) the type of gametes used (fresh embryo, frozen embryo, donated semen), and (5) the treatment indication (male factor, ovulation factor, tubal factor, other factor). Finally, the following sensitivity analyses were performed to test the robustness of our results: We applied a sibling design comparing siblings born to the same mother but discordant for exposure and outcome. By use of this approach, we accounted for potential confounding from genetic and family specific factors contributing to both the underlying parental infertility and the development of childhood epilepsy. These analyses were adjusted for maternal age at the index birth, smoking during pregnancy, and the child´s year of birth. Second, the criterion for epilepsy was restricted to both a primary diagnosis of epilepsy and redemption of at least two prescriptions for antiepileptic drugs. In further analyses, children diagnosed with a chromosomal anomaly in the Danish National Patient Register were excluded, or children only receiving an epilepsy diagnosis or antiepileptic drugs before 28 days of life were excluded. Furthermore, the primary analyses were carried out as complete-case analyses. Finally, all analyses of IVF or intracytoplasmic sperm injection were adjusted for treatment indication.
Ethical Approval
The study was approved by the State Serum Institute, Statistics Denmark, and the Danish Data Protection Agency (reference 2014-41-2686). Studies based on Danish register data do not require approval from ethics committees.
RESULTS
Maternal and infant characteristics of the 565,116 included pregnancies are presented in Table 1 . As expected, the proportion of children conceived by fertility treatment increased over the study period. Women conceiving after fertility treatment tended to be older, more educated, more frequently primiparous, of Western origin, and less likely to smoke during pregnancy than women conceiving spontaneously. A slightly larger percentage of the ovulation inductionor intrauterine insemination-treated women had a history of epilepsy compared with women who conceived following IVF, intracytoplasmic sperm injection, or spontaneously. During 7,844,119 person-years at risk, 8,071 children (1.4%) developed epilepsy; 2,699 children were identified only from the Danish National Patient Register, 1,275 children were identified only from the Danish National Prescription Registry, whereas 4,097 children were identified from both registers. A total of 1,574 children were diagnosed with idiopathic generalized epilepsy, and 1,732 children were diagnosed with focal epilepsy. The median follow-up time was 14 years. During follow-up, 32,184 children (5.7%) were censored due to death or emigration.
Compared with spontaneously conceived children, the risk of epilepsy was slightly higher in children conceived after ovulation induction or intrauterine insemination (HR: 1.15; 95% CI: 1.00, 1.31; Table 2 ). The association was more pronounced for specific subtypes of epilepsy, idiopathic generalized epilepsy and focal epilepsy (Table 3) . With respect to hormonal treatment, only treatment with clomiphene citrate was associated with an increased risk of epilepsy (Table 4) . This result was consistent using a sibling design (HR: 2.07; 95% CI: 1.05, 4.08).
IVF or intracytoplasmic sperm injection was not associated with an increased risk of childhood epilepsy (Table 2) . However, when assessing the risk of specific subtypes of epilepsy, we saw an association with idiopathic generalized epilepsy (HR: 1.43; 95% CI: 0.99, 2.05) but not with focal epilepsy (Table 3) . We observed no clear patterns of association regarding the type of procedure, the type of gamete, or the treatment indication (Table 4) .
The association between ovulation induction or intrauterine insemination and childhood epilepsy was attenuated when a diagnosis of epilepsy plus two prescriptions for antiepileptic drugs were required. The results of the remaining sensitivity analyses were similar to those reported.
DISCUSSION
In this large cohort study, we found that children conceived after ovulation induction or intrauterine insemination were at slightly increased risk of childhood epilepsy and that the risk was related to the use of clomiphene citrate. For IVF or intracytoplasmic sperm injection, our analyses suggested a small increased risk of idiopathic generalized epilepsy, a subtype of epilepsy believed to be of polygenic origin. 25 The present study has several methodologic strengths. The large sample size and the possibility to perform sibling analyses allowed us to assess differences in risk of developing epilepsy for exposed and unexposed sib pairs, which keeps maternal genetic and other family specific nontime varying influences constant. Sibling designs are particularly suitable for studying prenatal exposures and childhood outcomes as in the present study. 26 However, parental infertility can be caused by both stable factors, for example genetics, and factors that may change between pregnancies, such as lifestyle factors or parental age. However, we aimed to diminish these potential biases by adjusting the sibling analyses for maternal age and smoking, as well as the child's year of birth. Unfortunately, we could not assess the association between IVF or intracytoplasmic sperm injection and idiopathic generalized epilepsy in a sibling analysis approach because of the limited number of children born after either treatment who developed this subtype of epilepsy.
Another strength of the present study was the use of nationwide health registers to obtain detailed and valid information about exposures and outcomes. The coverage of the Danish IVF register is believed to be close to 100%. 12 Information on hormonal treatment from redeemed prescriptions may lead to exposure misclassification if compliance with the prescribed medication is low. However, women seeking fertility treatment are highly motivated to adhere to the treatment, and thus high compliance is expected. Furthermore, the hormones used to identify children born after ovulation induction or intrauterine insemination are only prescribed for fertility treatment. Children developing epilepsy were identified from two different data sources to ensure completeness of case identification. Epilepsy diagnoses in the Danish National Patient Register have previously been validated among adults with a reported positive predictive value of 81%. 27 In addition, the redemption of at least two prescriptions for antiepileptic drugs was required to ensure that the child had epilepsy. However, the subtype classification of childhood epilepsy in the Danish National Patient Register may be less precise and subject to nondifferential misclassification, which may have Adjusted for maternal age at birth, maternal smoking during pregnancy, maternal educational level, maternal ethnicity, maternal diagnosis of epilepsy before birth, and child's year of birth.
ICSI indicates intracytoplasmic sperm injection; IUI, intrauterine insemination; OI, ovulation induction.
attenuated the reported associations. If parents who conceive after fertility treatment are more prone to seek health care than parents who conceive spontaneously, exposed children could be diagnosed more frequently 9 or earlier in the course of disease. This could lead to differential misclassification of the outcome and overestimation of the association. Although this may be true for some disorders, it is less likely to have biased our results, because epileptic seizures in children prompt immediate health care contact, in most circumstances. Loss to follow-up after birth is unlikely to have influenced our results, because only few children were censored due to emigration or death during the follow-up period. Furthermore, we applied multiple imputation to avoid selection due to missing data. However, restricting our study population to live-born children may have attenuated the associations even though this potential bias would have been minimized by accounting for some of the common causes of prenatal death and childhood epilepsy. 28 The associations reported in the present study may reflect treatment effects or possibly residual confounding by parental characteristics that cause both infertility and childhood epilepsy. This source of potential confounding was addressed in the sibling design of clomiphene citrate exposure. The risk of epilepsy was substantial in the sibling analysis further corroborating that exposure to clomiphene citrate may be responsible for the increased risk of child epilepsy. Periconceptional treatment with clomiphene citrate has been associated with offspring neural tube defects in a previous animal study, 29 although this finding remains controversial in human studies. 30, 31 Our study supports the hypothesis that clomiphene citrate may have an impact on the developing central nervous system. However, the biologic mechanism by which clomiphene citrate administration before ovulation may induce epilepsy in the offspring remains unknown. Young et al. 32 showed that clomiphene citrate accumulates in the body over consecutive cycles, and hormone sensitivity may start during early embryonic stages (the first weeks after fertilization). 33 One may speculate that clomiphene citrate affects the epigenetic regulation at this early stage of brain development, 34 resulting in a lower threshold for seizures in the child. As the association between IVF or intracytoplasmic sperm injection and idiopathic generalized epilepsy in the offspring could not be assessed in a sibling analysis, we cannot rule out the possibility of confounding due to uncontrolled nontime varying parental characteristics. Furthermore, the association was limited to a subtype of epilepsy believed to be of genetic origin, suggesting that the association may be attributable to parental genetics causing both infertility and epilepsy in the child.
An association between fertility treatment and childhood epilepsy has previously been shown in a study of some 80,000 singletons from the Danish National Birth Cohort (1997) (1998) (1999) (2000) (2001) (2002) (2003) followed to a median age of 3.3 years. Results related to ovulation induction or intrauterine insemination were similar to those related to IVF or intracytoplasmic sperm injection with an increased incidence rate of childhood epilepsy of around 80%. In addition, the study showed an increased risk in infertile couples receiving no fertility treatment (incidence rate Adjusted for maternal age at birth, maternal smoking during pregnancy, maternal educational level, maternal ethnicity, maternal diagnosis of epilepsy before birth, and child's year of birth.
b As monotherapy. ratio 1.38). 8 However, the information on fertility and fertility treatment was self-reported, and potential underreporting of less invasive types of fertility treatment may explain the association with infertility, that is, if ovulation induction-or intrauterine insemination-treated women are misclassified into the infertile, untreated group. Similarly, in a study of 16,120 children conceived by IVF with a median follow-up time of 5.5 years, Källén et al. 9 reported an association between IVF or intracytoplasmic sperm injection and childhood epilepsy in the crude analyses. However, this association disappeared after adjustment for potential confounders, including years of unwanted childlessness (adjusted odds ratio 1.14; 95% CI: 0.77, 1.70). These previous studies identified children with epilepsy by hospital diagnoses only, 8, 9 whereas we were also able to use prescriptions for antiepileptic drugs. Unfortunately, duration of infertility is not recorded in any of the Danish national health registers, and thus we were unable to include this information in our analyses. Klemetti et al. 35, 36 reported a tendency toward a small increased risk of childhood epilepsy in 2,911 children conceived after IVF and 3,912 children conceived after ovulation induction or intrauterine insemination compared with spontaneously conceived children. However, these children were only followed until the age of 2 years. In addition, a cohort study aiming to identify risk factors of childhood epilepsy showed an association with assisted reproductive technology. 37 However, these studies did not account sufficiently for potential confounders, including parental infertility.
CONCLUSION
The results of our study suggest that children conceived by ovulation induction or intrauterine insemination with clomiphene citrate may have a small increased risk of childhood epilepsy. Additional studies targeting this treatment are needed, because alternative hormonal treatment for ovulation induction and intrauterine insemination is available. 38 Furthermore, children conceived by IVF or intracytoplasmic sperm injection may be at slightly increased risk of idiopathic generalized epilepsy. However, this association may be due to characteristics of the parents related to both parental infertility and epilepsy in the offspring rather than the treatments per se. Future studies are needed that assess the risk of idiopathic generalized epilepsy after IVF or intracytoplasmic sperm injection.
